• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Goy Gives Insights Into the Future Management of Lymphoma and Multiple Myeloma

by | May 6, 2024 | Uncategorized

Dr Goy discusses the impact of CAR T-cell therapy on the lymphoma and multiple myeloma treatment paradigms and his anticipations for the future of hematologic oncology. Read More

Dr Jagannath on the Patient Population in the LINKER-MM1 Trial in Multiple Myeloma

by | May 3, 2024 | Uncategorized

Sundar Jagannath, MBBS, discusses the patient population evaluated in the LINKER-MM1 trial of linvoseltamab in relapsed/refractory multiple myeloma. Read More

NXC-201 Receives Orphan Drug Designation in European Union for Multiple Myeloma

by | May 3, 2024 | Uncategorized

The CAR T-cell therapy NXC-201 has received orphan drug designation by the European Commission for patients with multiple myeloma. Read More

Homing in on Currently Recruiting Clinical Trials With Practice Changing Implications in Lymphoma and Myeloma

by | May 2, 2024 | Uncategorized

Leland Metheny, MD, discusses ongoing clinical trials and their implications for the field of hematologic oncology. Read More

Dr Anderson on the FDA ODAC Decision Regarding Cilta-Cel in R/R Multiple Myeloma

by | Apr 29, 2024 | Uncategorized

Kenneth C. Anderson, MD, discusses the recent FDA ODAC decision regarding the use of cilta-cel in relapsed/refractory multiple myeloma. Read More

Dr Jagannath on the Potential Role for Linvoseltamab in R/R Multiple Myeloma

by | Apr 25, 2024 | Uncategorized

Sundar Jagannath, discusses the potential role for linvoseltamab in relapsed/refractory multiple myeloma. Read More
« Older Entries
Next Entries »

Recent Content

  • Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma
  • IVIG Supplementation Reduces Infection Risk in Patients With Multiple Myeloma Receiving Teclistamab
  • Combination induces durable responses in advanced multiple myeloma
  • Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes
  • Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma
  • Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial
  • Addition of Elotuzumab to Backbone Treatment Regimens for Multiple Myeloma: An Updated Meta-Analysis of Randomized Clinical Trials
  • Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma
  • A Year of Resilience: Looking Back After a Myeloma Diagnosis
  • Real-World Outcomes Show Efficacy, Safety of Ciltacabtagene Autoleucel in Relapsed, Refractory Multiple Myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT